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2007-2008 Influenza Season 
Week 7, ending February 16, 2008 
 (All data are preliminary and may change as more reports are received.) 
 
Synopsis:  During week 7 (February 10 - 16, 2008), influenza activity continued to increase in the 
United States.   
o Two thousand three hundred forty (34.0%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza was above the epidemic 
threshold for the sixth consecutive week. 
o The proportion of outpatient visits for influenza-like illness (ILI) and acute respiratory illness 
(ARI) was above national baseline levels. ILI increased in six of the nine regions compared 
to week 6, and was above region-specific baselines in all nine regions.  All nine regions 
reported ARI at or above their region specific baselines.   
o Forty-nine states reported widespread influenza activity; one state reported regional 
influenza activity; and the District of Columbia reported local influenza activity. 
 
National and Regional Summary of Select Surveillance Components 
 
  Data for current week Data cumulative for the season 
  
Sentinel 
Provider 
ILI* 
DoD and 
VA ARI* 
% pos. 
for flu†
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity‡  
A 
(H1) 
A 
(H3) 
A 
Unsub-
typed 
B Pediatric Deaths 
Nation Elevated Elevated 34.0% 50 of 51  1266 2156 8956 2457 22 
New 
England Elevated Elevated 22.4% 6 of 6 34 17 293 235 0 
Mid-
Atlantic Elevated Elevated 21.7% 3 of 3 57 20 339 379 3 
East North 
Central Elevated Elevated 50.1% 5 of 5 119 532 347 223 3 
West 
North 
Central Elevated Elevated 26.3% 7 of 7 62 65 851 182 0 
South 
Atlantic Elevated Elevated 31.8% 8 of 9 191 676 2119 424 1 
East 
South 
Central Elevated Elevated 42.9% 4 of 4 21 301 22 14 4 
West South 
Central Elevated Elevated 34.9% 4 of 4 86 304 3999 472 7 
Mountain Elevated Elevated 27.7% 8 of 8 325 172 567 346 2 
Pacific Elevated Elevated 17.5% 5 of 5 371 69 419 182 2 
* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline 
† National data are for current week; regional data are for the most recent three weeks 
‡ Includes all 50 states and the District of Columbia 
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Laboratory Surveillance:  During week 7, WHO and NREVSS laboratories reported 6,889 
specimens tested for influenza viruses, 2,340 (34.0%) of which were positive, including 47 influenza 
A (H1) viruses, 379 influenza A (H3) viruses, 1,432 influenza A viruses that were not subtyped, and 
482 influenza B viruses.   
 
Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 109,089 
specimens for influenza viruses and 14,835 (13.6%) were positive. Among the 14,835 influenza 
viruses, 12,378 (83.4%) were influenza A viruses and 2,457 (16.6%) were influenza B viruses.  
Three thousand four hundred twenty-two (27.6%) of the 12,378 influenza A viruses have been 
subtyped: 1,266 (37.0%) were influenza A (H1) viruses and 2,156 (63.0%) were influenza A (H3) 
viruses. 
 
Although influenza A (H1) viruses predominated through mid-January, an increasing proportion of 
subtyped influenza A viruses are influenza A (H3) viruses. Influenza A (H3) viruses were reported 
more frequently than influenza A (H1) viruses during January 20–February 9.  During week 6, 
influenza A (H3) became the predominant virus for the season overall.  This season influenza A 
(H3) viruses have been reported more frequently than A (H1) viruses nationally, as well as in five of 
the nine surveillance regions (East North Central, East South Central, South Atlantic, West North 
Central, and West South Central).  Influenza A (H1) viruses have predominated circulation this 
season in the remaining four regions (Mid-Atlantic, Mountain, New England, and Pacific). 
 
U.S. WHO/NREVSS Collaborating Laboratories
National Summary, 2007-08
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Antigenic Characterization:  CDC has antigenically characterized 280 influenza viruses [141 
influenza A (H1N1), 70 influenza A (H3N2), and 69 influenza B viruses] collected by U.S. 
laboratories since September 30, 2007. 
 
Influenza A (H1N1) [141] 
• One hundred twenty-four (88%) of the 141 viruses were characterized as A/Solomon 
Islands/3/2006, the influenza A (H1N1) component of the 2007-08 influenza vaccine 
for the Northern Hemisphere and the 2008 influenza A (H1N1) component for the 
Southern Hemisphere. 
• Seventeen (12%) of the 141 viruses showed somewhat reduced titers with antisera 
produced against A/Solomon Islands/3/2006. 
 
Influenza A (H3N2) [70] 
• Twelve (17%) of the 70 viruses were characterized as A/Wisconsin/67/2005-like, the 
influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern 
Hemisphere. 
• Fifty-five (79%) of the 70 viruses were characterized as A/Brisbane/10/2007-like.  
A/Brisbane/10/2007-like viruses are a recent antigenic variant which evolved from, 
but are antigenically distinct from, A/Wisconsin/67/2005-like.  A/Brisbane/10/2007-
like virus is the recommended influenza A (H3N2) component for the 2008 Southern 
Hemisphere vaccine. 
• Three (4%) of the 70 viruses showed somewhat reduced titers with antisera 
produced against A/Wisconsin/67/2005 and A/Brisbane/10/2007. 
 
 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [69] 
  
Victoria lineage [4] 
• Four (6%) of the 69 influenza B viruses characterized belong to the B/Victoria 
lineage of viruses. 
o Two (50%) of these 4 viruses were characterized as B/Ohio/01/2005-like. The 
recommended influenza B component for the 2007-08 influenza vaccine is a 
B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage.  
B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain. 
o Two (50%) of these 4 viruses showed somewhat reduced titers with antisera 
produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.  
 
Yamagata lineage [65] 
• Sixty-five (94%) of the 69 viruses were identified as belonging to the B/Yamagata 
lineage of viruses. 
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Antiviral Resistance: In the United States, two groups of antiviral drugs have been approved by 
FDA for use in treating or preventing influenza infections.  These two groups of antiviral drugs are: 
neuraminidase inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and 
rimantidine). A description of these drugs can be found at: 
http://www.cdc.gov/flu/protect/antiviral/index.htm.  
 
Neuraminidase Inhibitor Antiviral Drugs: Small numbers of influenza viruses resistant to 
the neuraminidase inhibitor oseltamivir have been detected in the United States.  Of the 471 
influenza A and B viruses tested for antiviral resistance so far this season, 27 (5.7%) have 
been found to be resistant to oseltamivir.  Currently all of the resistant viruses are H1N1 
viruses, with 27 (8.7%) of all H1N1 viruses exhibiting a genetic mutation that confers 
oseltamivir resistance.  All tested viruses retain their sensitivity to zanamivir.  Additional 
information on antiviral resistance can be found at: 
http://www.cdc.gov/flu/about/qa/antiviralresistance.htm 
 
Adamantane Antiviral Drugs: Resistance to the adamantanes continues to be high.  
Among 282 influenza A viruses tested, 88 (31.2%) are resistant to adamantanes, including 
98.6% of H3N2 viruses and 7.2% of H1N1 viruses.  The adamantanes are not effective 
against influenza B viruses.   
 
Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, 
and persisting high levels of resistance to the adamantanes in both H3N2 and H1N1 
viruses, CDC continues to recommend the use of oseltamivir and zanamivir for the 
treatment or prevention of influenza.  Use of amantadine or rimantadine is not 
recommended.  Guidance on influenza antiviral use can be found at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 7, 8.2% of all deaths 
reported through the 122 Cities Mortality Reporting System were reported as due to P&I. This 
percentage is above the epidemic threshold of 7.2% for week 7.  Including week 7, P&I mortality 
has been above threshold for six consecutive weeks. 
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Influenza-Associated Pediatric Mortality: Twelve influenza-associated pediatric deaths were 
reported to CDC during week 7 from ten states [AR, CA, CO(2), FL, IL, IN, MS, NYC, TX(2), and 
WI].  Since September 30, 2007, CDC has received a total of 22 reports of influenza-associated 
pediatric deaths that occurred during the current season.   
Number of Influenza-Associated Pediatric Deaths
by Week of Death:
2005-06 season to present
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Influenza-Associated Pediatric Hospitalizations:  Laboratory-confirmed influenza-associated 
pediatric hospitalizations are monitored in two population-based surveillance networks: the New 
Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
During November 4, 2007-February 9, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the NVSN for children 0-4 years old was 1.83 per 
10,000.   
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2007- 08 and Previous 2 Seasons
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During September 30 – February 2, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the EIP for children 0–17 years old was 0.36 per 10,000.  
For children aged 0-4 years and 5-17 years, the rate was 1.0 per 10,000 and 0.1 per 10,000, 
respectively.  
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children Aged 0-4 and 5-17 yrs, 2007-2008 and 
Previous 2 Seasons
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Outpatient Illness Surveillance:  Nationwide during week 7, 6.4% of outpatient visits reported 
through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness 
(ILI), which is above the national baseline of 2.2%.  On a regional level, the percentage of visits for 
ILI increased in six of the nine regions compared to last week and ranged from 4.1% to 10.1%.  All 
nine regions reported ILI above their region-specific baselines.  
 
Starting in week 5, New York City began reporting ILI data collected electronically from emergency 
departments city-wide, adding approximately 60,000 additional patient visits per week to the U.S. 
Influenza Sentinel Provider Surveillance Network.  Retrospective reports were submitted for all 
earlier weeks this season.  While this change increases the total patient visits per week by 
approximately 15%, it is not expected to influence the national ILI outpatient visit percentage after 
population weighting, but may have a larger impact on the Mid-Atlantic regional ILI percentage. 
 
During week 7, 3.7% of patient visits to Department of Veteran’s Affairs (VA) and Department of 
Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was 
above the national baseline of 3.2%.  On a regional level, the percentage of visits for ARI ranged 
from 1.8% to 4.3%, and was at or above the region-specific baselines in all nine regions.  The 
percentage of visits reported for ARI was at or above age-specific baselines in the 5-17 years, 18-
49 years, 50-64 years, and >64 years age groups.   
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Percentage of Visits for ILI & ARI Reported
by Sentinel Providers and BioSense Outpatient Facilities,
National Summary
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Percentage of Visits for ARI by Age Group Reported by 
DoD/VA Outpatient Clinics - National Summary
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: During 
week 7 the following influenza activity was reported: 
• Widespread activity was reported by 49 states (Alabama, Alaska, Arizona, Arkansas, 
California, Colorado, Connecticut, Delaware, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, 
Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New 
Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, 
Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, 
Washington, Wisconsin, West Virginia, and Wyoming). 
• Regional activity was reported by 1 state (Florida). 
• The District of Columbia reported local influenza activity. 
 
 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: February 22, 2008.
  
  
  
